The plateau phase begins for most participants around weeks 40 to 48, with an average plateau arrival at week 43.2
The least-squares mean percentage change in body weight from baseline was -7.2% in the 1 mg group, -12.9% in the 4 mg group (starting at 2 mg), -17.1% in the combined 4 mg groups, -17.5% in the combined 8 mg groups, and -17.5% in the 12 mg group, compared with -1.6% in the placebo group
These symptoms, while uncomfortable, are part of the normal adaptation process and are consistent with the clinical trial experience
Clinical teams must expect both physical and emotional effects
Participants reported a 75.8% reduction in pain on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale
In this study, Bbs5 / mice showed impaired nest-building behavior (Figure 1F), indicative of potential learning and/or motor deficits